These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 17296993)
1. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. Cianfoni A; Niku S; Imbesi SG AJNR Am J Neuroradiol; 2007 Feb; 28(2):272-7. PubMed ID: 17296993 [TBL] [Abstract][Full Text] [Related]
2. Conventional and advanced magnetic resonance imaging in tumefactive demyelination. Saini J; Chatterjee S; Thomas B; Kesavadas C Acta Radiol; 2011 Dec; 52(10):1159-68. PubMed ID: 22025739 [TBL] [Abstract][Full Text] [Related]
3. Utility of proton MR spectroscopy for differentiating typical and atypical primary central nervous system lymphomas from tumefactive demyelinating lesions. Lu SS; Kim SJ; Kim HS; Choi CG; Lim YM; Kim EJ; Kim DY; Cho SH AJNR Am J Neuroradiol; 2014 Feb; 35(2):270-7. PubMed ID: 23928144 [TBL] [Abstract][Full Text] [Related]
4. Proton MR spectroscopy of tumefactive demyelinating lesions. Saindane AM; Cha S; Law M; Xue X; Knopp EA; Zagzag D AJNR Am J Neuroradiol; 2002 Sep; 23(8):1378-86. PubMed ID: 12223381 [TBL] [Abstract][Full Text] [Related]
5. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. Kalis M; Bowen BC; Quencer RM AJNR Am J Neuroradiol; 2007 Sep; 28(8):1427; author reply 1427-8. PubMed ID: 17846183 [No Abstract] [Full Text] [Related]
6. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy. Malhotra HS; Jain KK; Agarwal A; Singh MK; Yadav SK; Husain M; Krishnani N; Gupta RK Mult Scler; 2009 Feb; 15(2):193-203. PubMed ID: 19181773 [TBL] [Abstract][Full Text] [Related]
7. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. Poptani H; Gupta RK; Roy R; Pandey R; Jain VK; Chhabra DK AJNR Am J Neuroradiol; 1995 Sep; 16(8):1593-603. PubMed ID: 7502961 [TBL] [Abstract][Full Text] [Related]
8. Assessment of citrullinated myelin by 1H-MR spectroscopy in early-onset multiple sclerosis. Oguz KK; Kurne A; Aksu AO; Karabulut E; Serdaroglu A; Teber S; Haspolat S; Senbil N; Kurul S; Anlar B AJNR Am J Neuroradiol; 2009 Apr; 30(4):716-21. PubMed ID: 19147724 [TBL] [Abstract][Full Text] [Related]
9. Proton MR spectroscopy of central neurocytoma using short and long echo time: new proofs for the existence of glycine and glutamate. Liu M; Yue Q; Isobe T; Matsumura A; Li J; Yang Z; Quan H; Xing H; Gong Q Acad Radiol; 2012 Jul; 19(7):779-84. PubMed ID: 22503892 [TBL] [Abstract][Full Text] [Related]
10. Effect of voxel position on single-voxel MR spectroscopy findings. Ricci PE; Pitt A; Keller PJ; Coons SW; Heiserman JE AJNR Am J Neuroradiol; 2000 Feb; 21(2):367-74. PubMed ID: 10696025 [TBL] [Abstract][Full Text] [Related]
11. Correlation of spectroscopy and magnetization transfer imaging in the evaluation of demyelinating lesions and normal appearing white matter in multiple sclerosis. Hiehle JF; Lenkinski RE; Grossman RI; Dousset V; Ramer KN; Schnall MD; Cohen JA; Gonzalez-Scarano F Magn Reson Med; 1994 Sep; 32(3):285-93. PubMed ID: 7984060 [TBL] [Abstract][Full Text] [Related]
12. Proton MR spectroscopy and magnetization transfer ratio in multiple sclerosis: correlative findings of active versus irreversible plaque disease. Kimura H; Grossman RI; Lenkinski RE; Gonzalez-Scarano F AJNR Am J Neuroradiol; 1996 Sep; 17(8):1539-47. PubMed ID: 8883654 [TBL] [Abstract][Full Text] [Related]
13. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Arnold DL; Matthews PM; Francis GS; O'Connor J; Antel JP Ann Neurol; 1992 Mar; 31(3):235-41. PubMed ID: 1637131 [TBL] [Abstract][Full Text] [Related]
14. Axonal damage in multiple sclerosis plaques: a combined magnetic resonance imaging and 1H-magnetic resonance spectroscopy study. Simone IL; Tortorella C; Federico F; Liguori M; Lucivero V; Giannini P; Carrara D; Bellacosa A; Livrea P J Neurol Sci; 2001 Jan; 182(2):143-50. PubMed ID: 11137520 [TBL] [Abstract][Full Text] [Related]
15. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. Bitsch A; Bruhn H; Vougioukas V; Stringaris A; Lassmann H; Frahm J; Brück W AJNR Am J Neuroradiol; 1999 Oct; 20(9):1619-27. PubMed ID: 10543631 [TBL] [Abstract][Full Text] [Related]
16. Proton magnetic resonance spectroscopy (MRS) of metastatic brain tumors: variations of metabolic profile. Chernov MF; Hayashi M; Izawa M; Ono Y; Hori T Int J Clin Oncol; 2006 Oct; 11(5):375-84. PubMed ID: 17058135 [TBL] [Abstract][Full Text] [Related]
17. Increased concentrations of glutamate and glutamine in normal-appearing white matter of patients with multiple sclerosis and normal MR imaging brain scans. Tisell A; Leinhard OD; Warntjes JB; Aalto A; Smedby Ö; Landtblom AM; Lundberg P PLoS One; 2013; 8(4):e61817. PubMed ID: 23613944 [TBL] [Abstract][Full Text] [Related]
18. Serial diffusion-weighted MR imaging and proton MR spectroscopy of acute large demyelinating brain lesions: case report. Rovira A; Pericot I; Alonso J; Rio J; Grivé E; Montalban X AJNR Am J Neuroradiol; 2002; 23(6):989-94. PubMed ID: 12063231 [TBL] [Abstract][Full Text] [Related]
19. Axonal damage but no increased glial cell activity in the normal-appearing white matter of patients with clinically isolated syndromes suggestive of multiple sclerosis using high-field magnetic resonance spectroscopy. Wattjes MP; Harzheim M; Lutterbey GG; Klotz L; Schild HH; Träber F AJNR Am J Neuroradiol; 2007 Sep; 28(8):1517-22. PubMed ID: 17846203 [TBL] [Abstract][Full Text] [Related]